Subcutaneous degradation of biosynthetic human growth hormone in growth hormone deficient patients
- PMID: 3389047
- DOI: 10.1530/acta.0.1180154
Subcutaneous degradation of biosynthetic human growth hormone in growth hormone deficient patients
Abstract
The aim of the present study was to look further into the question of local degradation of sc injected human GH in GH deficient patients. A comparison was made of serum GH levels after constant iv and sc infusion of the same amount of GH (33 ng.kg-1.min-1) in the same 9 GH deficient patients. A 3-h lag period was interposed between the iv and the sc infusion. Iv infusion was continued for 3 h. All 9 subjects subsequently received sc infusion for 19 h and five of them continued for additionally 24 h. The mean steady state serum GH level in the nine patients was 23.1 +/- 5.1 micrograms/l after iv and 6.8 +/- micrograms/l after sc administration (P less than 0.01). Extension of the sc infusion period in 4 of the subjects did not significantly alter the serum GH level (P less than 0.15), implying that a steady state was reached. The GH in the infusion system was stable throughout a 24-h period. We therefore conclude that sc injected GH is degraded locally to a substantial extent.
Similar articles
-
Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.J Clin Endocrinol Metab. 1995 Aug;80(8):2410-8. doi: 10.1210/jcem.80.8.7543114. J Clin Endocrinol Metab. 1995. PMID: 7543114 Clinical Trial.
-
Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites.J Clin Endocrinol Metab. 1990 Jan;70(1):207-14. doi: 10.1210/jcem-70-1-207. J Clin Endocrinol Metab. 1990. PMID: 2294131 Clinical Trial.
-
Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices.J Clin Endocrinol Metab. 1990 Jun;70(6):1616-23. doi: 10.1210/jcem-70-6-1616. J Clin Endocrinol Metab. 1990. PMID: 2189886
-
Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.J Clin Endocrinol Metab. 1989 Jan;68(1):22-8. doi: 10.1210/jcem-68-1-22. J Clin Endocrinol Metab. 1989. PMID: 2491864
-
Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men.J Clin Endocrinol Metab. 1985 Nov;61(5):846-50. doi: 10.1210/jcem-61-5-846. J Clin Endocrinol Metab. 1985. PMID: 3930551
Cited by
-
Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration.J Pharm Sci. 2020 Jan;109(1):191-205. doi: 10.1016/j.xphs.2019.08.005. Epub 2019 Aug 10. J Pharm Sci. 2020. PMID: 31408633 Free PMC article. Review.
-
Current guidelines for adult GH replacement.Rev Endocr Metab Disord. 2005 Jan;6(1):63-70. doi: 10.1007/s11154-005-5226-y. Rev Endocr Metab Disord. 2005. PMID: 15711916 Review. No abstract available.
-
The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency.Br J Clin Pharmacol. 1999 Mar;47(3):273-8. doi: 10.1046/j.1365-2125.1999.00892.x. Br J Clin Pharmacol. 1999. PMID: 10215751 Free PMC article. Clinical Trial.
-
Effects of recombinant human growth hormone in patients with severe sepsis.Ann Surg. 1992 Dec;216(6):648-55. doi: 10.1097/00000658-199212000-00006. Ann Surg. 1992. PMID: 1466618 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Miscellaneous